nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluorouracil—Nucleic Acid Synthesis Inhibitors—Cytarabine—lymphatic system cancer	0.649	1	CiPCiCtD
Fluorouracil—SLC29A1—Fludarabine—lymphatic system cancer	0.0967	0.338	CbGbCtD
Fluorouracil—SLC29A1—Cytarabine—lymphatic system cancer	0.066	0.231	CbGbCtD
Fluorouracil—MTHFR—Methotrexate—lymphatic system cancer	0.0206	0.0721	CbGbCtD
Fluorouracil—TYMS—Methotrexate—lymphatic system cancer	0.0175	0.0614	CbGbCtD
Fluorouracil—ABCC3—Vincristine—lymphatic system cancer	0.015	0.0526	CbGbCtD
Fluorouracil—ABCG2—Teniposide—lymphatic system cancer	0.0128	0.0449	CbGbCtD
Fluorouracil—ABCC3—Methotrexate—lymphatic system cancer	0.0091	0.0318	CbGbCtD
Fluorouracil—ABCG2—Mitoxantrone—lymphatic system cancer	0.00897	0.0314	CbGbCtD
Fluorouracil—CYP1A2—Carmustine—lymphatic system cancer	0.00787	0.0275	CbGbCtD
Fluorouracil—SLC22A7—Methotrexate—lymphatic system cancer	0.00711	0.0249	CbGbCtD
Fluorouracil—ABCC4—Methotrexate—lymphatic system cancer	0.00695	0.0243	CbGbCtD
Fluorouracil—ABCG2—Vincristine—lymphatic system cancer	0.00617	0.0216	CbGbCtD
Fluorouracil—CYP2C9—Teniposide—lymphatic system cancer	0.00476	0.0167	CbGbCtD
Fluorouracil—ABCG2—Methotrexate—lymphatic system cancer	0.00374	0.0131	CbGbCtD
Fluorouracil—ALB—Methotrexate—lymphatic system cancer	0.00258	0.00901	CbGbCtD
Fluorouracil—TYMS—Podofilox—Teniposide—lymphatic system cancer	0.000445	0.4	CbGdCrCtD
Fluorouracil—TYMS—Vinorelbine—Vincristine—lymphatic system cancer	0.000265	0.238	CbGdCrCtD
Fluorouracil—TYMS—Vinblastine—Vincristine—lymphatic system cancer	0.000182	0.164	CbGdCrCtD
Fluorouracil—TYMS—Azacitidine—Fludarabine—lymphatic system cancer	0.000113	0.102	CbGdCrCtD
Fluorouracil—TYMS—Azacitidine—Cytarabine—lymphatic system cancer	0.000107	0.096	CbGdCrCtD
Fluorouracil—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.000104	0.00164	CcSEcCtD
Fluorouracil—Vomiting—Mechlorethamine—lymphatic system cancer	0.000104	0.00163	CcSEcCtD
Fluorouracil—Nervous system disorder—Fludarabine—lymphatic system cancer	0.000104	0.00163	CcSEcCtD
Fluorouracil—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.000104	0.00163	CcSEcCtD
Fluorouracil—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.000104	0.00163	CcSEcCtD
Fluorouracil—Stomatitis—Carmustine—lymphatic system cancer	0.000104	0.00163	CcSEcCtD
Fluorouracil—Urinary tract infection—Carmustine—lymphatic system cancer	0.000103	0.00162	CcSEcCtD
Fluorouracil—Rash—Mechlorethamine—lymphatic system cancer	0.000103	0.00162	CcSEcCtD
Fluorouracil—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.000103	0.00162	CcSEcCtD
Fluorouracil—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000103	0.00162	CcSEcCtD
Fluorouracil—Speech disorder—Methotrexate—lymphatic system cancer	0.000102	0.00161	CcSEcCtD
Fluorouracil—Pneumonia—Vincristine—lymphatic system cancer	0.000102	0.0016	CcSEcCtD
Fluorouracil—Anorexia—Fludarabine—lymphatic system cancer	0.000101	0.00159	CcSEcCtD
Fluorouracil—Extravasation—Methotrexate—lymphatic system cancer	0.000101	0.00158	CcSEcCtD
Fluorouracil—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.0001	0.00157	CcSEcCtD
Fluorouracil—Neuropathy peripheral—Vincristine—lymphatic system cancer	9.95e-05	0.00156	CcSEcCtD
Fluorouracil—Myocardial infarction—Vincristine—lymphatic system cancer	9.95e-05	0.00156	CcSEcCtD
Fluorouracil—Pneumonia—Mitoxantrone—lymphatic system cancer	9.95e-05	0.00156	CcSEcCtD
Fluorouracil—Feeling abnormal—Teniposide—lymphatic system cancer	9.94e-05	0.00156	CcSEcCtD
Fluorouracil—Stomatitis—Vincristine—lymphatic system cancer	9.9e-05	0.00155	CcSEcCtD
Fluorouracil—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	9.75e-05	0.00153	CcSEcCtD
Fluorouracil—Nausea—Mechlorethamine—lymphatic system cancer	9.72e-05	0.00153	CcSEcCtD
Fluorouracil—Myocardial infarction—Mitoxantrone—lymphatic system cancer	9.69e-05	0.00152	CcSEcCtD
Fluorouracil—Alopecia—Bleomycin—lymphatic system cancer	9.67e-05	0.00152	CcSEcCtD
Fluorouracil—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	9.66e-05	0.00152	CcSEcCtD
Fluorouracil—Stomatitis—Mitoxantrone—lymphatic system cancer	9.64e-05	0.00151	CcSEcCtD
Fluorouracil—Urinary tract infection—Mitoxantrone—lymphatic system cancer	9.61e-05	0.00151	CcSEcCtD
Fluorouracil—Conjunctivitis—Mitoxantrone—lymphatic system cancer	9.61e-05	0.00151	CcSEcCtD
Fluorouracil—Haemoglobin—Carmustine—lymphatic system cancer	9.6e-05	0.00151	CcSEcCtD
Fluorouracil—Urticaria—Teniposide—lymphatic system cancer	9.58e-05	0.0015	CcSEcCtD
Fluorouracil—Herpes simplex—Methotrexate—lymphatic system cancer	9.56e-05	0.0015	CcSEcCtD
Fluorouracil—Haemorrhage—Carmustine—lymphatic system cancer	9.55e-05	0.0015	CcSEcCtD
Fluorouracil—Body temperature increased—Teniposide—lymphatic system cancer	9.53e-05	0.0015	CcSEcCtD
Fluorouracil—Erythema—Bleomycin—lymphatic system cancer	9.52e-05	0.00149	CcSEcCtD
Fluorouracil—Paraesthesia—Fludarabine—lymphatic system cancer	9.52e-05	0.00149	CcSEcCtD
Fluorouracil—Hypoaesthesia—Carmustine—lymphatic system cancer	9.5e-05	0.00149	CcSEcCtD
Fluorouracil—Dyspnoea—Fludarabine—lymphatic system cancer	9.45e-05	0.00148	CcSEcCtD
Fluorouracil—Dyspepsia—Fludarabine—lymphatic system cancer	9.33e-05	0.00146	CcSEcCtD
Fluorouracil—Ulcer—Methotrexate—lymphatic system cancer	9.31e-05	0.00146	CcSEcCtD
Fluorouracil—Dysarthria—Methotrexate—lymphatic system cancer	9.31e-05	0.00146	CcSEcCtD
Fluorouracil—Sinusitis—Mitoxantrone—lymphatic system cancer	9.28e-05	0.00146	CcSEcCtD
Fluorouracil—Agranulocytosis—Mitoxantrone—lymphatic system cancer	9.23e-05	0.00145	CcSEcCtD
Fluorouracil—Decreased appetite—Fludarabine—lymphatic system cancer	9.21e-05	0.00145	CcSEcCtD
Fluorouracil—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	9.15e-05	0.00144	CcSEcCtD
Fluorouracil—Inflammation—Methotrexate—lymphatic system cancer	9.08e-05	0.00143	CcSEcCtD
Fluorouracil—Hypoaesthesia—Vincristine—lymphatic system cancer	9.07e-05	0.00142	CcSEcCtD
Fluorouracil—Pain—Fludarabine—lymphatic system cancer	9.06e-05	0.00142	CcSEcCtD
Fluorouracil—Haemoglobin—Mitoxantrone—lymphatic system cancer	8.92e-05	0.0014	CcSEcCtD
Fluorouracil—Rhinitis—Mitoxantrone—lymphatic system cancer	8.9e-05	0.0014	CcSEcCtD
Fluorouracil—Hypersensitivity—Teniposide—lymphatic system cancer	8.89e-05	0.00139	CcSEcCtD
Fluorouracil—Haemorrhage—Mitoxantrone—lymphatic system cancer	8.88e-05	0.00139	CcSEcCtD
Fluorouracil—Pharyngitis—Mitoxantrone—lymphatic system cancer	8.81e-05	0.00138	CcSEcCtD
Fluorouracil—Anaemia—Bleomycin—lymphatic system cancer	8.8e-05	0.00138	CcSEcCtD
Fluorouracil—Feeling abnormal—Fludarabine—lymphatic system cancer	8.73e-05	0.00137	CcSEcCtD
Fluorouracil—Pruritus—Teniposide—lymphatic system cancer	8.53e-05	0.00134	CcSEcCtD
Fluorouracil—Arrhythmia—Carmustine—lymphatic system cancer	8.53e-05	0.00134	CcSEcCtD
Fluorouracil—Leukopenia—Bleomycin—lymphatic system cancer	8.52e-05	0.00134	CcSEcCtD
Fluorouracil—Alopecia—Carmustine—lymphatic system cancer	8.44e-05	0.00132	CcSEcCtD
Fluorouracil—Body temperature increased—Fludarabine—lymphatic system cancer	8.38e-05	0.00132	CcSEcCtD
Fluorouracil—Erythema—Carmustine—lymphatic system cancer	8.31e-05	0.0013	CcSEcCtD
Fluorouracil—Diarrhoea—Teniposide—lymphatic system cancer	8.25e-05	0.0013	CcSEcCtD
Fluorouracil—Chest pain—Bleomycin—lymphatic system cancer	8.11e-05	0.00127	CcSEcCtD
Fluorouracil—Myalgia—Bleomycin—lymphatic system cancer	8.11e-05	0.00127	CcSEcCtD
Fluorouracil—Alopecia—Vincristine—lymphatic system cancer	8.05e-05	0.00126	CcSEcCtD
Fluorouracil—Coma—Methotrexate—lymphatic system cancer	8.05e-05	0.00126	CcSEcCtD
Fluorouracil—Discomfort—Bleomycin—lymphatic system cancer	8.01e-05	0.00126	CcSEcCtD
Fluorouracil—Arrhythmia—Mitoxantrone—lymphatic system cancer	7.93e-05	0.00124	CcSEcCtD
Fluorouracil—Alopecia—Mitoxantrone—lymphatic system cancer	7.84e-05	0.00123	CcSEcCtD
Fluorouracil—Confusional state—Bleomycin—lymphatic system cancer	7.84e-05	0.00123	CcSEcCtD
Fluorouracil—Vision blurred—Carmustine—lymphatic system cancer	7.83e-05	0.00123	CcSEcCtD
Fluorouracil—Hypersensitivity—Fludarabine—lymphatic system cancer	7.81e-05	0.00123	CcSEcCtD
Fluorouracil—Anaphylactic shock—Bleomycin—lymphatic system cancer	7.77e-05	0.00122	CcSEcCtD
Fluorouracil—Oedema—Bleomycin—lymphatic system cancer	7.77e-05	0.00122	CcSEcCtD
Fluorouracil—Erythema—Mitoxantrone—lymphatic system cancer	7.73e-05	0.00121	CcSEcCtD
Fluorouracil—Infection—Bleomycin—lymphatic system cancer	7.72e-05	0.00121	CcSEcCtD
Fluorouracil—Anaemia—Carmustine—lymphatic system cancer	7.68e-05	0.00121	CcSEcCtD
Fluorouracil—Vomiting—Teniposide—lymphatic system cancer	7.67e-05	0.0012	CcSEcCtD
Fluorouracil—Sepsis—Methotrexate—lymphatic system cancer	7.64e-05	0.0012	CcSEcCtD
Fluorouracil—Thrombocytopenia—Bleomycin—lymphatic system cancer	7.61e-05	0.00119	CcSEcCtD
Fluorouracil—Rash—Teniposide—lymphatic system cancer	7.6e-05	0.00119	CcSEcCtD
Fluorouracil—Dermatitis—Teniposide—lymphatic system cancer	7.6e-05	0.00119	CcSEcCtD
Fluorouracil—Headache—Teniposide—lymphatic system cancer	7.56e-05	0.00119	CcSEcCtD
Fluorouracil—Pruritus—Fludarabine—lymphatic system cancer	7.5e-05	0.00118	CcSEcCtD
Fluorouracil—Leukopenia—Carmustine—lymphatic system cancer	7.44e-05	0.00117	CcSEcCtD
Fluorouracil—Anorexia—Bleomycin—lymphatic system cancer	7.41e-05	0.00116	CcSEcCtD
Fluorouracil—Thrombophlebitis—Methotrexate—lymphatic system cancer	7.39e-05	0.00116	CcSEcCtD
Fluorouracil—Anaemia—Vincristine—lymphatic system cancer	7.33e-05	0.00115	CcSEcCtD
Fluorouracil—Vision blurred—Mitoxantrone—lymphatic system cancer	7.28e-05	0.00114	CcSEcCtD
Fluorouracil—Photosensitivity—Methotrexate—lymphatic system cancer	7.28e-05	0.00114	CcSEcCtD
Fluorouracil—Hypotension—Bleomycin—lymphatic system cancer	7.26e-05	0.00114	CcSEcCtD
Fluorouracil—Diarrhoea—Fludarabine—lymphatic system cancer	7.25e-05	0.00114	CcSEcCtD
Fluorouracil—Convulsion—Carmustine—lymphatic system cancer	7.2e-05	0.00113	CcSEcCtD
Fluorouracil—Nausea—Teniposide—lymphatic system cancer	7.16e-05	0.00112	CcSEcCtD
Fluorouracil—Anaemia—Mitoxantrone—lymphatic system cancer	7.14e-05	0.00112	CcSEcCtD
Fluorouracil—Leukopenia—Vincristine—lymphatic system cancer	7.1e-05	0.00111	CcSEcCtD
Fluorouracil—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	7.08e-05	0.00111	CcSEcCtD
Fluorouracil—Chest pain—Carmustine—lymphatic system cancer	7.08e-05	0.00111	CcSEcCtD
Fluorouracil—Myalgia—Carmustine—lymphatic system cancer	7.08e-05	0.00111	CcSEcCtD
Fluorouracil—Paraesthesia—Bleomycin—lymphatic system cancer	6.98e-05	0.0011	CcSEcCtD
Fluorouracil—Dyspnoea—Bleomycin—lymphatic system cancer	6.93e-05	0.00109	CcSEcCtD
Fluorouracil—Leukopenia—Mitoxantrone—lymphatic system cancer	6.92e-05	0.00109	CcSEcCtD
Fluorouracil—Convulsion—Vincristine—lymphatic system cancer	6.87e-05	0.00108	CcSEcCtD
Fluorouracil—Confusional state—Carmustine—lymphatic system cancer	6.84e-05	0.00107	CcSEcCtD
Fluorouracil—Oedema—Carmustine—lymphatic system cancer	6.78e-05	0.00106	CcSEcCtD
Fluorouracil—Decreased appetite—Bleomycin—lymphatic system cancer	6.76e-05	0.00106	CcSEcCtD
Fluorouracil—Myalgia—Vincristine—lymphatic system cancer	6.76e-05	0.00106	CcSEcCtD
Fluorouracil—Infection—Carmustine—lymphatic system cancer	6.74e-05	0.00106	CcSEcCtD
Fluorouracil—Vomiting—Fludarabine—lymphatic system cancer	6.74e-05	0.00106	CcSEcCtD
Fluorouracil—Convulsion—Mitoxantrone—lymphatic system cancer	6.7e-05	0.00105	CcSEcCtD
Fluorouracil—Rash—Fludarabine—lymphatic system cancer	6.68e-05	0.00105	CcSEcCtD
Fluorouracil—Dermatitis—Fludarabine—lymphatic system cancer	6.68e-05	0.00105	CcSEcCtD
Fluorouracil—Pain—Bleomycin—lymphatic system cancer	6.65e-05	0.00104	CcSEcCtD
Fluorouracil—Thrombocytopenia—Carmustine—lymphatic system cancer	6.64e-05	0.00104	CcSEcCtD
Fluorouracil—Headache—Fludarabine—lymphatic system cancer	6.64e-05	0.00104	CcSEcCtD
Fluorouracil—Tachycardia—Carmustine—lymphatic system cancer	6.62e-05	0.00104	CcSEcCtD
Fluorouracil—Myalgia—Mitoxantrone—lymphatic system cancer	6.58e-05	0.00103	CcSEcCtD
Fluorouracil—Chest pain—Mitoxantrone—lymphatic system cancer	6.58e-05	0.00103	CcSEcCtD
Fluorouracil—Lethargy—Methotrexate—lymphatic system cancer	6.52e-05	0.00102	CcSEcCtD
Fluorouracil—Discomfort—Mitoxantrone—lymphatic system cancer	6.5e-05	0.00102	CcSEcCtD
Fluorouracil—Oedema—Vincristine—lymphatic system cancer	6.48e-05	0.00102	CcSEcCtD
Fluorouracil—Anaphylactic shock—Vincristine—lymphatic system cancer	6.48e-05	0.00102	CcSEcCtD
Fluorouracil—Anorexia—Carmustine—lymphatic system cancer	6.47e-05	0.00101	CcSEcCtD
Fluorouracil—Infection—Vincristine—lymphatic system cancer	6.43e-05	0.00101	CcSEcCtD
Fluorouracil—Feeling abnormal—Bleomycin—lymphatic system cancer	6.4e-05	0.00101	CcSEcCtD
Fluorouracil—Osteoarthritis—Methotrexate—lymphatic system cancer	6.39e-05	0.001	CcSEcCtD
Fluorouracil—Confusional state—Mitoxantrone—lymphatic system cancer	6.36e-05	0.000998	CcSEcCtD
Fluorouracil—Nervous system disorder—Vincristine—lymphatic system cancer	6.35e-05	0.000997	CcSEcCtD
Fluorouracil—Thrombocytopenia—Vincristine—lymphatic system cancer	6.34e-05	0.000995	CcSEcCtD
Fluorouracil—Hypotension—Carmustine—lymphatic system cancer	6.34e-05	0.000995	CcSEcCtD
Fluorouracil—Oedema—Mitoxantrone—lymphatic system cancer	6.31e-05	0.00099	CcSEcCtD
Fluorouracil—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	6.31e-05	0.00099	CcSEcCtD
Fluorouracil—Nausea—Fludarabine—lymphatic system cancer	6.3e-05	0.000988	CcSEcCtD
Fluorouracil—Infection—Mitoxantrone—lymphatic system cancer	6.27e-05	0.000983	CcSEcCtD
Fluorouracil—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	6.18e-05	0.00097	CcSEcCtD
Fluorouracil—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	6.17e-05	0.000969	CcSEcCtD
Fluorouracil—Urticaria—Bleomycin—lymphatic system cancer	6.17e-05	0.000969	CcSEcCtD
Fluorouracil—Anorexia—Vincristine—lymphatic system cancer	6.17e-05	0.000969	CcSEcCtD
Fluorouracil—Tachycardia—Mitoxantrone—lymphatic system cancer	6.16e-05	0.000966	CcSEcCtD
Fluorouracil—Body temperature increased—Bleomycin—lymphatic system cancer	6.14e-05	0.000964	CcSEcCtD
Fluorouracil—Insomnia—Carmustine—lymphatic system cancer	6.14e-05	0.000963	CcSEcCtD
Fluorouracil—Irritability—Methotrexate—lymphatic system cancer	6.1e-05	0.000958	CcSEcCtD
Fluorouracil—Paraesthesia—Carmustine—lymphatic system cancer	6.09e-05	0.000956	CcSEcCtD
Fluorouracil—Hypotension—Vincristine—lymphatic system cancer	6.05e-05	0.00095	CcSEcCtD
Fluorouracil—Dyspnoea—Carmustine—lymphatic system cancer	6.05e-05	0.000949	CcSEcCtD
Fluorouracil—Somnolence—Carmustine—lymphatic system cancer	6.03e-05	0.000947	CcSEcCtD
Fluorouracil—Anorexia—Mitoxantrone—lymphatic system cancer	6.01e-05	0.000944	CcSEcCtD
Fluorouracil—Ataxia—Methotrexate—lymphatic system cancer	6.01e-05	0.000944	CcSEcCtD
Fluorouracil—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	5.9e-05	0.000926	CcSEcCtD
Fluorouracil—Decreased appetite—Carmustine—lymphatic system cancer	5.9e-05	0.000926	CcSEcCtD
Fluorouracil—Hypotension—Mitoxantrone—lymphatic system cancer	5.89e-05	0.000925	CcSEcCtD
Fluorouracil—Insomnia—Vincristine—lymphatic system cancer	5.86e-05	0.000919	CcSEcCtD
Fluorouracil—Gastrointestinal disorder—Carmustine—lymphatic system cancer	5.86e-05	0.000919	CcSEcCtD
Fluorouracil—Paraesthesia—Vincristine—lymphatic system cancer	5.81e-05	0.000913	CcSEcCtD
Fluorouracil—Pain—Carmustine—lymphatic system cancer	5.8e-05	0.000911	CcSEcCtD
Fluorouracil—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	5.75e-05	0.000902	CcSEcCtD
Fluorouracil—Hypersensitivity—Bleomycin—lymphatic system cancer	5.73e-05	0.000899	CcSEcCtD
Fluorouracil—Paraesthesia—Mitoxantrone—lymphatic system cancer	5.66e-05	0.000889	CcSEcCtD
Fluorouracil—Decreased appetite—Vincristine—lymphatic system cancer	5.63e-05	0.000884	CcSEcCtD
Fluorouracil—Dyspnoea—Mitoxantrone—lymphatic system cancer	5.62e-05	0.000883	CcSEcCtD
Fluorouracil—Somnolence—Mitoxantrone—lymphatic system cancer	5.61e-05	0.00088	CcSEcCtD
Fluorouracil—Gastrointestinal disorder—Vincristine—lymphatic system cancer	5.59e-05	0.000878	CcSEcCtD
Fluorouracil—Feeling abnormal—Carmustine—lymphatic system cancer	5.59e-05	0.000877	CcSEcCtD
Fluorouracil—Dyspepsia—Mitoxantrone—lymphatic system cancer	5.55e-05	0.000871	CcSEcCtD
Fluorouracil—Pain—Vincristine—lymphatic system cancer	5.54e-05	0.000869	CcSEcCtD
Fluorouracil—Pruritus—Bleomycin—lymphatic system cancer	5.5e-05	0.000863	CcSEcCtD
Fluorouracil—Decreased appetite—Mitoxantrone—lymphatic system cancer	5.48e-05	0.00086	CcSEcCtD
Fluorouracil—Eosinophilia—Methotrexate—lymphatic system cancer	5.47e-05	0.000859	CcSEcCtD
Fluorouracil—Pain—Mitoxantrone—lymphatic system cancer	5.39e-05	0.000846	CcSEcCtD
Fluorouracil—Body temperature increased—Carmustine—lymphatic system cancer	5.36e-05	0.000842	CcSEcCtD
Fluorouracil—Pancytopenia—Methotrexate—lymphatic system cancer	5.25e-05	0.000824	CcSEcCtD
Fluorouracil—Feeling abnormal—Mitoxantrone—lymphatic system cancer	5.2e-05	0.000816	CcSEcCtD
Fluorouracil—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	5.14e-05	0.000806	CcSEcCtD
Fluorouracil—Body temperature increased—Vincristine—lymphatic system cancer	5.12e-05	0.000804	CcSEcCtD
Fluorouracil—Photosensitivity reaction—Methotrexate—lymphatic system cancer	5.04e-05	0.000792	CcSEcCtD
Fluorouracil—Urticaria—Mitoxantrone—lymphatic system cancer	5.01e-05	0.000786	CcSEcCtD
Fluorouracil—Hypersensitivity—Carmustine—lymphatic system cancer	5e-05	0.000784	CcSEcCtD
Fluorouracil—Body temperature increased—Mitoxantrone—lymphatic system cancer	4.99e-05	0.000783	CcSEcCtD
Fluorouracil—Pneumonia—Methotrexate—lymphatic system cancer	4.96e-05	0.000778	CcSEcCtD
Fluorouracil—Vomiting—Bleomycin—lymphatic system cancer	4.94e-05	0.000776	CcSEcCtD
Fluorouracil—Infestation NOS—Methotrexate—lymphatic system cancer	4.93e-05	0.000773	CcSEcCtD
Fluorouracil—Infestation—Methotrexate—lymphatic system cancer	4.93e-05	0.000773	CcSEcCtD
Fluorouracil—Rash—Bleomycin—lymphatic system cancer	4.9e-05	0.000769	CcSEcCtD
Fluorouracil—Dermatitis—Bleomycin—lymphatic system cancer	4.9e-05	0.000768	CcSEcCtD
Fluorouracil—Stomatitis—Methotrexate—lymphatic system cancer	4.8e-05	0.000754	CcSEcCtD
Fluorouracil—Conjunctivitis—Methotrexate—lymphatic system cancer	4.79e-05	0.000752	CcSEcCtD
Fluorouracil—Hypersensitivity—Vincristine—lymphatic system cancer	4.77e-05	0.000749	CcSEcCtD
Fluorouracil—Epistaxis—Methotrexate—lymphatic system cancer	4.65e-05	0.000729	CcSEcCtD
Fluorouracil—Hypersensitivity—Mitoxantrone—lymphatic system cancer	4.65e-05	0.000729	CcSEcCtD
Fluorouracil—Diarrhoea—Carmustine—lymphatic system cancer	4.64e-05	0.000729	CcSEcCtD
Fluorouracil—Nausea—Bleomycin—lymphatic system cancer	4.62e-05	0.000725	CcSEcCtD
Fluorouracil—Agranulocytosis—Methotrexate—lymphatic system cancer	4.6e-05	0.000722	CcSEcCtD
Fluorouracil—Dizziness—Carmustine—lymphatic system cancer	4.49e-05	0.000704	CcSEcCtD
Fluorouracil—Haemoglobin—Methotrexate—lymphatic system cancer	4.45e-05	0.000698	CcSEcCtD
Fluorouracil—Diarrhoea—Vincristine—lymphatic system cancer	4.43e-05	0.000695	CcSEcCtD
Fluorouracil—Haemorrhage—Methotrexate—lymphatic system cancer	4.42e-05	0.000694	CcSEcCtD
Fluorouracil—Pharyngitis—Methotrexate—lymphatic system cancer	4.39e-05	0.000689	CcSEcCtD
Fluorouracil—Diarrhoea—Mitoxantrone—lymphatic system cancer	4.32e-05	0.000677	CcSEcCtD
Fluorouracil—Vomiting—Carmustine—lymphatic system cancer	4.31e-05	0.000677	CcSEcCtD
Fluorouracil—Dizziness—Vincristine—lymphatic system cancer	4.28e-05	0.000672	CcSEcCtD
Fluorouracil—Rash—Carmustine—lymphatic system cancer	4.28e-05	0.000671	CcSEcCtD
Fluorouracil—Dermatitis—Carmustine—lymphatic system cancer	4.27e-05	0.000671	CcSEcCtD
Fluorouracil—Headache—Carmustine—lymphatic system cancer	4.25e-05	0.000667	CcSEcCtD
Fluorouracil—Vomiting—Vincristine—lymphatic system cancer	4.12e-05	0.000646	CcSEcCtD
Fluorouracil—Rash—Vincristine—lymphatic system cancer	4.08e-05	0.000641	CcSEcCtD
Fluorouracil—Dermatitis—Vincristine—lymphatic system cancer	4.08e-05	0.00064	CcSEcCtD
Fluorouracil—Headache—Vincristine—lymphatic system cancer	4.06e-05	0.000637	CcSEcCtD
Fluorouracil—Nausea—Carmustine—lymphatic system cancer	4.03e-05	0.000632	CcSEcCtD
Fluorouracil—Vomiting—Mitoxantrone—lymphatic system cancer	4.01e-05	0.000629	CcSEcCtD
Fluorouracil—Rash—Mitoxantrone—lymphatic system cancer	3.98e-05	0.000624	CcSEcCtD
Fluorouracil—Dermatitis—Mitoxantrone—lymphatic system cancer	3.97e-05	0.000624	CcSEcCtD
Fluorouracil—Headache—Mitoxantrone—lymphatic system cancer	3.95e-05	0.00062	CcSEcCtD
Fluorouracil—Alopecia—Methotrexate—lymphatic system cancer	3.91e-05	0.000613	CcSEcCtD
Fluorouracil—Erythema—Methotrexate—lymphatic system cancer	3.85e-05	0.000604	CcSEcCtD
Fluorouracil—Nausea—Vincristine—lymphatic system cancer	3.85e-05	0.000604	CcSEcCtD
Fluorouracil—Nausea—Mitoxantrone—lymphatic system cancer	3.75e-05	0.000588	CcSEcCtD
Fluorouracil—Vision blurred—Methotrexate—lymphatic system cancer	3.63e-05	0.00057	CcSEcCtD
Fluorouracil—Anaemia—Methotrexate—lymphatic system cancer	3.56e-05	0.000559	CcSEcCtD
Fluorouracil—Leukopenia—Methotrexate—lymphatic system cancer	3.45e-05	0.000541	CcSEcCtD
Fluorouracil—Convulsion—Methotrexate—lymphatic system cancer	3.34e-05	0.000524	CcSEcCtD
Fluorouracil—Chest pain—Methotrexate—lymphatic system cancer	3.28e-05	0.000514	CcSEcCtD
Fluorouracil—Myalgia—Methotrexate—lymphatic system cancer	3.28e-05	0.000514	CcSEcCtD
Fluorouracil—Discomfort—Methotrexate—lymphatic system cancer	3.24e-05	0.000508	CcSEcCtD
Fluorouracil—Confusional state—Methotrexate—lymphatic system cancer	3.17e-05	0.000497	CcSEcCtD
Fluorouracil—Anaphylactic shock—Methotrexate—lymphatic system cancer	3.14e-05	0.000493	CcSEcCtD
Fluorouracil—Infection—Methotrexate—lymphatic system cancer	3.12e-05	0.00049	CcSEcCtD
Fluorouracil—Nervous system disorder—Methotrexate—lymphatic system cancer	3.08e-05	0.000484	CcSEcCtD
Fluorouracil—Thrombocytopenia—Methotrexate—lymphatic system cancer	3.08e-05	0.000483	CcSEcCtD
Fluorouracil—Anorexia—Methotrexate—lymphatic system cancer	3e-05	0.00047	CcSEcCtD
Fluorouracil—Hypotension—Methotrexate—lymphatic system cancer	2.94e-05	0.000461	CcSEcCtD
Fluorouracil—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	2.86e-05	0.000449	CcSEcCtD
Fluorouracil—Insomnia—Methotrexate—lymphatic system cancer	2.84e-05	0.000446	CcSEcCtD
Fluorouracil—Paraesthesia—Methotrexate—lymphatic system cancer	2.82e-05	0.000443	CcSEcCtD
Fluorouracil—Dyspnoea—Methotrexate—lymphatic system cancer	2.8e-05	0.00044	CcSEcCtD
Fluorouracil—Somnolence—Methotrexate—lymphatic system cancer	2.79e-05	0.000438	CcSEcCtD
Fluorouracil—Dyspepsia—Methotrexate—lymphatic system cancer	2.77e-05	0.000434	CcSEcCtD
Fluorouracil—Decreased appetite—Methotrexate—lymphatic system cancer	2.73e-05	0.000429	CcSEcCtD
Fluorouracil—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	2.71e-05	0.000426	CcSEcCtD
Fluorouracil—Pain—Methotrexate—lymphatic system cancer	2.69e-05	0.000422	CcSEcCtD
Fluorouracil—Feeling abnormal—Methotrexate—lymphatic system cancer	2.59e-05	0.000406	CcSEcCtD
Fluorouracil—Urticaria—Methotrexate—lymphatic system cancer	2.5e-05	0.000392	CcSEcCtD
Fluorouracil—Body temperature increased—Methotrexate—lymphatic system cancer	2.48e-05	0.00039	CcSEcCtD
Fluorouracil—Hypersensitivity—Methotrexate—lymphatic system cancer	2.32e-05	0.000363	CcSEcCtD
Fluorouracil—Pruritus—Methotrexate—lymphatic system cancer	2.22e-05	0.000349	CcSEcCtD
Fluorouracil—Diarrhoea—Methotrexate—lymphatic system cancer	2.15e-05	0.000337	CcSEcCtD
Fluorouracil—Dizziness—Methotrexate—lymphatic system cancer	2.08e-05	0.000326	CcSEcCtD
Fluorouracil—Vomiting—Methotrexate—lymphatic system cancer	2e-05	0.000314	CcSEcCtD
Fluorouracil—Rash—Methotrexate—lymphatic system cancer	1.98e-05	0.000311	CcSEcCtD
Fluorouracil—Dermatitis—Methotrexate—lymphatic system cancer	1.98e-05	0.000311	CcSEcCtD
Fluorouracil—Headache—Methotrexate—lymphatic system cancer	1.97e-05	0.000309	CcSEcCtD
Fluorouracil—Nausea—Methotrexate—lymphatic system cancer	1.87e-05	0.000293	CcSEcCtD
